[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]
[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]
[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]
[1]Manne,SatyanarayanaReddy;Srinivasan,ThirumalaiRajan;Sajja,Eswaraiah;Rebelli,Pradeep;Nadendla,HareeshKumar;Bairy,KondalReddy;Ghojala,VenkatReddy;Chepyala,KistaReddy[OrganicPreparationsandProceduresInternational,2013,vol.45,#6,p.510-514]
[1]OrganicPreparationsandProceduresInternational,2013,vol.45,p.510-514
[2]OrganicPreparationsandProceduresInternational,2016,vol.48,p.481-491
[3]OrganicPreparationsandProceduresInternational,2016,vol.48,p.481-491
[4]OrganicPreparationsandProceduresInternational,2016,vol.48,p.481-491
Title: Dhillon S, et al. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2009;9(5):331-50.
Title: Akamata K, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther. 2014 Apr 3;16(2):R86.
Title: Iglarz M, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014 Nov 24;118(2):333-9.